Caspar da Cunha-Bang

11PUBLICATIONS
52CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Innate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Sep 18, 2026
A functional prognostic model predicts progression-free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Jan 28, 2026
Hypertension affects survival and treatment in chronic lymphocytic leukemia.

Noomi Vainer, Christian Brieghel, Klaus Rostgaard

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Apr 18, 2025
Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Carsten U Niemann, Julie Dubois, Kazem Nasserinejad

|Mar 01, 2024
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.

Christian Brieghel, Caspar da Cunha-Bang, Jindrich Mourek

Pageof 2

Frequent Collaborators

11 joint publications

Carsten Utoft Niemann

7 joint publications

Christian Brieghel

6 joint publications

Arnon P Kater

5 joint publications

Mark-David Levin